Inhibitory short synthetic oligodeoxynucleotides and lupus
1 Department of Microbiology, Columbia University, New York, NY 10032
2 Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA
Arthritis Research & Therapy 2009, 11:116 doi:10.1186/ar2726
See related research by Lenert et al., http://arthritis-research.com/content/11/3/R79Published: 26 June 2009
B cells and antigen-presenting cells express a group of intracellular Toll-like receptors (TLRs) that recognize nucleic acids and can be accessed only when apoptotic debris or immune complexes are internalized by B-cell receptors or Fc receptors. This results in rapid cell activation and release of inflammatory mediators that perpetuate the autoantibody response. TLR-7 and TLR-9 are required to generate autoantibodies to RNA and DNA, respectively. Synthetic oligodeoxynucleotides that inhibit the activity of these intracellular TLRs attenuate systemic lupus erythematosus in mouse models and may be of therapeutic benefit in human systemic lupus erythematosus.